TCR2 Therapeutics

Biotech

Adaptimmune absorbs TCR² to extend cash runway, broaden pipeline

The combined entity is trading under Adaptimmune’s Nasdaq ticker and is led by its CEO Adrian Rawcliffe.

James Waldron Mar 6, 2023 9:30am

Graphic of employees walking out depicting layoffs

Layoffs still battering biotech, with Big Pharmas piling on pain

Feb 1, 2023 10:50am

graphic of a saw cutting off the branch of a tree with employees on it resembling axing staff

TCR² first began layoffs back in August

Jan 13, 2023 11:00am

immune system fighting cancer cells

TCR2's cell therapy racks up 22% response rate in solid tumors

Sep 28, 2022 9:40am

Close-up of two people shaking hands with other people in the background

TCR2 taps ElevateBio to manufacture T-cell therapy for phase 2

Nov 10, 2020 8:00am

cancer newspaper

TCR2's T-cell therapy curbs solid tumors in early phase 1 data

Jul 27, 2020 10:45am